Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: A systematic review of the literature

Clinical Lung Cancer

Volumn 16, Issue 2, 2015, Pages 71-79

  Kaster, Tyler S ^a,b   Yaremko, Brian ^a   Palma, David A ^a   Rodrigues, George B ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Biological effective dose; Clinical outcomes; Hypofractionated radiotherapy; NSCLC; Systematic review

Indexed keywords

CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; HUMAN; LUNG NEOPLASMS; PATHOLOGY; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION INJURIES; SURVIVAL RATE;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 84922981043     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.08.002     Document Type: Review

References (67)

1. National Cancer Institute. SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/statfacts/html/lungb.html.
2. C. Le Pechoux Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data Oncologist 16 2011 672 681
3. C.A. Perez, K. Stanley, and P. Rubin A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group Cancer 45 1980 2744 2753
4. W.J. Curran, R. Paulus, and C.J. Langer Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410 J Natl Cancer Inst 103 2011 1452 1460
5. J.D. Bradley, R. Paulus, and R. Komaki A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: results on radiation dose in RTOG 0617 J Clin Oncol 31 2013 7501
6. M. Mehta, R. Scrimger, R. Mackie, B. Paliwal, R. Chappell, and J.F. Fowler A new approach to dose escalation in non-small-cell lung cancer Int J Radiat Oncol Biol Phys 49 2001 23 33
7. J.D. Bradley, K. Bae, and M.V. Graham Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117 J Clin Oncol 28 2010 2475 2480
8. B. Movsas, C. Hu, and J. Sloan Quality of life (QOL) analysis of the randomized radiation (RT) dose-escalation NSCLC trial (RTOG 0617): the rest of the story Int J Radiat Oncol Biol Phys 87 2013 S1 S2
9. J.D. Cox Are the results of RTOG 0617 mysterious? Int J Radiat Oncol Biol Phys 82 2012 1042 1044
10. J.F. Fowler, and R. Chappell Non-small cell lung tumors repopulate rapidly during radiation therapy Int J Radiat Oncol Biol Phys 46 2000 516 517
11. M. Saunders, S. Dische, A. Barrett, A. Harvey, D. Gibson, and M. Parmar Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee Lancet 350 1997 161 165
12. L.S. Pemberton, O.S. Din, P.M. Fisher, and M.Q. Hatton Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-centre retrospective study of outcome Clin Oncol 21 2009 161 167
13. O.S. Din, S.V. Harden, and E. Hudson Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres Radiother Oncol 109 2013 8 12
14. L. Pirtoli, M. Bindi, A. Bellezza, F. Pepi, and E. Tucci Unfavorable experience with hypofractionated radiotherapy in unresectable lung cancer Tumori 78 1992 305 310
15. M.A. Socinski, C. Zhang, and J.E. Herndon 2nd Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity Ann Oncol 15 2004 1033 1041
16. S.L. Prewett, S. Aslam, M.V. Williams, and D. Gilligan The management of lung cancer: a UK survey of oncologists Clin Oncol (R Coll Radiol) 24 2012 402 409
17. J. Maguire, N. O'Rourke, and R. McNememin SOCCAR: internationally resonant results from a randomised trial based on UK clinical practise Thorax 67 2012 A47
18. D.M. Cannon, M.P. Mehta, and J.B. Adkison Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer J Clin Oncol 31 2013 4343 4348
19. J. Healy In regard to Machtay et al Int J Radiat Oncol Biol Phys 84 2012 302 303
20. M. Machtay, K. Bae, and B. Movsas Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 82 2012 425 434
21. M. Machtay, C. Washam, and P. Devine Pilot study of accelerated radiotherapy with concurrent chemotherapy for stage III non-small cell lung cancer Semin Oncol 32 2005 S9 S12
22. J. Belderbos, L. Uitterhoeve, and N. van Zandwijk Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973) Eur J Cancer 43 2007 114 121
23. A.L. Uitterhoeve, M.G. Koolen, and M. Van Os Rob Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with non-small cell lung cancer Radiat Oncol 2 2007 27
24. P.G. Tsoutsou, M.E. Froudarakis, D. Bouros, and M.I. Koukourakis Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC) Anticancer Res 28 2008 1349 1354
25. S. Bral, M. Duchateau, and H. Versmessen Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy Cancer 116 2010 241 250
26. K. Matsuura, T. Kimura, and K. Kashiwado Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer Int J Clin Oncol 14 2009 408 415
27. F. Casas, N. Viñolas, and F. Ferrer Long-term results of a phase II trial of induction paclitaxel-carboplatin followed by concurrent radiation therapy and weekly paclitaxel and consolidation paclitaxel-carboplatin in stage III non-small cell lung cancer J Thorac Oncol 6 2011 79 85
28. R. Carruthers, N. O'Rourke, N. Mohammed, J. Hicks, and I. Brisbane Toxicity of hypofractionated accelerated radiotherapy concurrent with chemotherapy for non-small cell carcinoma of the lung Clin Oncol (R Coll Radiol) 23 2011 561 562
29. Q. Lin, Y.E. Liu, and X.C. Ren Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial Radiat Oncol 8 2013 201
30. Y.E. Liu, Q. Lin, and F.J. Meng High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study Radiat Oncol 9 2013 13
31. C. Chen, W. Uyterlinde, J.J. Sonke, J. de Bois, M. van den Heuvel, and J. Belderbos Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy Radiother Oncol 108 2013 337 341
32. V. Donato, S. Arcangeli, and A. Monaco Moderately escalated hypofractionated (chemo) radiotherapy delivered with helical intensity-modulated technique in stage III unresectable non-small cell lung cancer Front Oncol 3 2013 286
33. M.M. van den Heuvel, W. Uyterlinde, and A.D. Vincent Additional weekly cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating Radiother Oncol 2013 In Press
34. A. Bearz, E. Minatel, and I.A. Rumeileh Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen BMC Cancer 13 2013 513
35. A.L. Schuster-Uitterhoeve, M.C. Hulshof, D. Gonzalez Gonzalez, M. Koolen, and P. Sminia Feasibility of curative radiotherapy with a concomitant boost technique in 33 patients with non-small cell lung cancer (NSCLC) Radiother Oncol 28 1993 247 251
36. M.V. Graham, T.E. Pajak, A.M. Herskovic, B. Emami, and C.A. Perez Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): long-term results Int J Radiat Oncol Biol Phys 31 1995 819 825
37. J. Bernier, J. Denekamp, and A. Rojas ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC Radiother Oncol 52 1999 149 156
38. L.N. Nguyen, R. Komaki, P. Allen, R.A. Schea, and L. Milas Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review Int J Radiat Oncol Biol Phys 44 1999 1053 1056
39. L.M. Sun, S.W. Leung, and C.J. Wang Concomitant boost radiation therapy for inoperable non-small-cell lung cancer: preliminary report of a prospective randomized study Int J Radiat Oncol Biol Phys 47 2000 413 418
40. C.L. Holloway, D. Robinson, and B. Murray Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer Radiother Oncol 73 2004 285 287
41. J.F. Lester, F.R. Macbeth, A.E. Brewster, J.B. Court, and N. Iqbal CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer Lung Cancer 45 2004 237 242
42. P. Thirion, O. Holmberg, and C.D. Collins Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy Radiother Oncol 71 2004 163 166
43. L. Kepka, D. Tyc-Szczepaniak, and K. Bujko Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer J Thorac Oncol 4 2009 853 861
44. S. Bral, M. Duchateau, and H. Versmessen Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable stage III non-small cell lung cancer using helical tomotherapy Int J Radiat Oncol Biol Phys 77 2010 1352 1359
45. Z.F. Zhu, M. Fan, and K.L. Wu A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer Radiother Oncol 98 2011 304 308
46. A. Monaco, C. Caruso, D. Giammarino, M. Cianciulli, M.C. Pressello, and V. Donato Radiotherapy for inoperable non-small cell lung cancer using helical tomotherapy Tumori 98 2011 86 89
47. A. Amini, S.H. Lin, C. Wei, P. Allen, J.D. Cox, and R. Komaki Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer Radiat Oncol 7 2012 33
48. A.J. McPartlin, S. Chaudhry, and R. Swindell The largest UK single centre series using hypofractionated radical radiotherapy for NSCLC in the very elderly Lung Cancer 81 2013 144
49. M.F. Osti, L. Agolli, and M. Valeriani Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer Int J Radiat Oncol Biol Phys 85 2013 e157 e163
50. T. Berghmans, M. Paesmans, and J.P. Sculier Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables Ther Adv Med Oncol 3 2011 127 138
51. A. Mauguen, C. Le Péchoux, and M.I. Saunders Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis J Clin Oncol 30 2012 2788 2797
52. C.P. Belani, W. Wang, and D.H. Johnson Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer J Clin Oncol 23 2005 3760 3767
53. M. Baumann, T. Herrmann, and R. Koch Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC) Radiother Oncol 100 2011 76 85
54. M. Partridge, M. Ramos, A. Sardaro, and M. Brada Dose escalation for non-small cell lung cancer: analysis and modelling of published literature Radiother Oncol 99 2011 6 11
55. M.K. Martel, H.K. Ten, and M.B. Hazuka Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients Lung Cancer 24 1999 31 37
56. J.D. Fenwick, A.E. Nahum, and Z.I. Malik Escalation and intensification of radiotherapy for stage III non-small cell lung cancer: opportunities for treatment improvement Clin Oncol 21 2009 343 360
57. R. Timmerman, R. McGarry, and C. Yiannoutsos Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer J Clin Oncol 24 2006 4833 4839
58. R. Timmerman, R. Paulus, and J. Galvin Stereotactic body radiation therapy for inoperable early stage lung cancer JAMA 303 2010 1070 1076
59. W. De Neve, and C. De Wagter Lethal pneumonitis in a phase I study of chemotherapy and IMRT for NSCLC: the need to investigate the accuracy of dose computation Radiother Oncol 75 2005 246 247
60. D.A. Palma, S. Senan, and K. Tsujnio Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis Int J Radiat Oncol Biol Phys 85 2013 444 450
61. L. Wang, S. Wu, and G. Ou Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer Lung Cancer 77 2012 89 96
62. A. Auperin, C. Le Pechoux, and E. Rolland Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer J Clin Oncol 28 2010 2181 2190
63. J. Feddock, S.M. Arnold, and B.J. Shelton Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study Int J Radiat Oncol Biol Phys 85 2013 1325 1331
64. S.D. Karam, Z.D. Horne, R.L. Hong, D. McRae, D. Duhamel, and N.M. Nasr Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer Radiat Oncol 8 2013 179
65. J.T. Hepel, J. Peter, and J.R. Hiatt Dosimetric feasibility of dose escalation using SBRT boost for stage III non-small cell lung cancer Front Oncol 2 2012 124
66. J. Bradley, G.A. Masters, and C. Hu An intergroup randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) chemoradiotherapy (CRT) +/- cetuximab (cetux) for stage III non-small cell lung cancer (NSCLC): results on cetux from RTOG 0617 J Thorac Oncol 8 2013 S3
67. D.R. Gomez, M. Gillin, and Z. Liao Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer Int J Radiat Oncol Biol Phys 86 2013 665 670